Prenatal hypoxia alters the early ontogeny of dopamine neurons

Anastasia Brandon1, Xiaoying Cui1,2, Wei Luan1

  • 1Queensland Brain Institute, The University of Queensland, St Lucia, QLD, Australia.

Insights

Prenatal hypoxia, a risk factor for schizophrenia, impairs early brain development of dopaminergic (DA) neurons. This study shows hypoxia retards DA neuron migration and alters presynaptic architecture, suggesting a convergent pathway for DA dysfunction in schizophrenia.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Psychiatry

Background:

  • Dopaminergic (DA) system dysfunction is central to schizophrenia pathophysiology.
  • Developmental risk factors like maternal immune activation and vitamin D deficiency impact early DA neuron differentiation.
  • Prenatal hypoxia is another established environmental risk factor for schizophrenia.

Purpose of the Study:

  • To investigate the effects of prenatal hypoxia on the developing dopaminergic system.
  • To explore how hypoxia influences DA neuron development, migration, and presynaptic function.

Main Methods:

  • Pregnant mice were exposed to hypoxia (10% oxygen) from embryonic day 10 to 12.
  • Embryonic brains were analyzed for DA neuron positioning and gene expression.
  • Postnatal day 10 striata were examined for tyrosine hydroxylase (TH) expression and DA release sites.

Main Results:

  • Prenatal hypoxia decreased dopaminergic progenitors and retarded early DA neuron migration.
  • Hypoxia reduced the expression of key receptors involved in DA neuron migration.
  • Postnatal analysis revealed reduced TH expression and altered DA release sites in the striatum.

Conclusions:

  • Prenatal hypoxia induces early alterations in the developing DA system.
  • These findings suggest a convergent mechanism for DA dysfunction across multiple schizophrenia risk factors.
  • Early DA system disruption may contribute to presynaptic DA dysfunction observed in schizophrenia patients.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
319